Holen Sie sich die Stockscreener-App
79.80
0.51%
-0.41
Handel nachbörslich:
79.85
0.05
+0.06%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt EW?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$80.21
Offen:
$80.18
24-Stunden-Volumen:
2.29M
Relative Volume:
0.59
Marktkapitalisierung:
$46.85B
Einnahmen:
$5.69B
Nettoeinkommen (Verlust:
$1.41B
KGV:
11.48
EPS:
6.95
Netto-Cashflow:
$577.90M
1W Leistung:
-2.41%
1M Leistung:
+1.85%
6M Leistung:
+13.47%
1J Leistung:
+21.44%
1-Tages-Spanne:
$79.51
$80.73
1-Wochen-Bereich:
$79.51
$82.67
52-Wochen-Spanne:
$64.00
$83.00
Edwards Lifesciences Corp Stock (EW) Company Profile
Firmenname
Edwards Lifesciences Corp
Sektor
Branche
Telefon
(949) 250-2500
Adresse
ONE EDWARDS WAY, IRVINE, CA
Vergleichen Sie EW mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
79.80 | 47.09B | 5.69B | 1.41B | 577.90M | 6.95 |
|
ABT
Abbott Laboratories
|
131.95 | 230.09B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
108.09 | 160.24B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
392.76 | 150.29B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
94.07 | 119.28B | 34.20B | 4.69B | 5.30B | 3.63 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-29 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-04-24 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Hochstufung | Stifel | Hold → Buy |
| 2025-01-16 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-07-31 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-07-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-07-25 | Herabstufung | Truist | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-05-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-02-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-28 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-03-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Herabstufung | Bernstein | Outperform → Underperform |
| 2023-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Herabstufung | Stifel | Buy → Hold |
| 2022-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Eingeleitet | Mizuho | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-29 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Eingeleitet | Truist | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-03-16 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-27 | Bestätigt | Citigroup | Buy |
| 2022-01-27 | Bestätigt | Evercore ISI | Outperform |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Buy |
| 2022-01-27 | Bestätigt | UBS | Neutral |
| 2021-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-12-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-30 | Bestätigt | Deutsche Bank | Hold |
| 2021-07-30 | Bestätigt | Jefferies | Buy |
| 2021-07-30 | Bestätigt | Morgan Stanley | Overweight |
| 2021-07-30 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-30 | Bestätigt | Stifel | Buy |
| 2021-07-30 | Bestätigt | UBS | Neutral |
| 2021-07-30 | Bestätigt | Wells Fargo | Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-04-05 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-11 | Bestätigt | Canaccord Genuity | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Underperform |
| 2020-04-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Bestätigt | Canaccord Genuity | Buy |
| 2019-09-23 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-24 | Bestätigt | BofA/Merrill | Buy |
| 2019-03-18 | Bestätigt | Canaccord Genuity | Buy |
| 2019-01-18 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Eingeleitet | Deutsche Bank | Hold |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-10-02 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Herabstufung | Guggenheim | Buy → Neutral |
Alle ansehen
Edwards Lifesciences Corp Aktie (EW) Neueste Nachrichten
Is This the Dip to Buy in Edwards Lifesciences Corporation2025 Earnings Impact & Community Trade Idea Sharing - beatles.ru
Is Edwards Lifesciences Corporation in a bullish channel2025 Market WrapUp & Safe Entry Zone Identification - beatles.ru
Edwards acquires Vectorious for $497M - BioWorld MedTech
Edwards Lifesciences’ TAVR growth continues as global demand rises - Yahoo Finance
Edwards Lifesciences Corporation stock trendline breakdown2025 Winners & Losers & Capital Efficiency Focused Ideas - Newser
Edwards buys remaining stake of Vectorious Medical Technologies and its heart implant - MassDevice
Edwards Lifesciences Acquires Israeli Medtech Firm Vectorious Medical for $497m Valuation - AInvest
What Fibonacci levels say about Edwards Lifesciences Corporation reboundWeekly Profit Report & Long-Term Growth Portfolio Plans - Newser
Is Edwards Lifesciences Corporation meeting your algorithmic filter criteriaMarket Sentiment Review & Real-Time Volume Trigger Notifications - Newser
Is it time to cut losses on Edwards Lifesciences CorporationMarket Growth Report & Reliable Entry Point Trade Alerts - Newser
Published on: 2025-09-03 02:50:15 - Newser
Using AI based signals to follow Edwards Lifesciences CorporationJuly 2025 Highlights & Fast Moving Market Watchlists - Newser
How to read the order book for Edwards Lifesciences CorporationJuly 2025 Opening Moves & Free Weekly Chart Analysis and Trade Guides - Newser
Building trade automation scripts for Edwards Lifesciences CorporationWeekly Profit Recap & Weekly Breakout Watchlists - Newser
Can Edwards Lifesciences Corporation stock recover from recent declineTrade Entry Summary & Low Volatility Stock Suggestions - Newser
Healthcare Stocks to Watch: argenx, ICON, and Edwards Lifesciences with Long-Term Potential - AInvest
Leerink Partners Lifts Edwards Lifesciences (EW) Price Target Amid Buybacks Focus - Yahoo Finance
Edwards Lifesciences Stock: Is EW Outperforming the Healthcare Sector? - Yahoo Finance
Is Edwards Lifesciences Corporation stock ready for a breakout2025 Top Decliners & Short-Term Swing Trade Alerts - Newser
Published on: 2025-09-01 12:29:31 - Newser
Signal strength of Edwards Lifesciences Corporation stock in tech scannersJuly 2025 Levels & Real-Time Stock Entry Alerts - Newser
Should you wait for a breakout in Edwards Lifesciences CorporationRecession Risk & Risk Controlled Stock Alerts - Newser
Forecasting Edwards Lifesciences Corporation price range with options data2025 Investor Takeaways & Weekly Chart Analysis and Guides - Newser
How institutional ownership impacts Edwards Lifesciences Corporation stockJuly 2025 Drop Watch & Fast Moving Trade Plans - Newser
Analyzing net buyer seller activity in Edwards Lifesciences CorporationWeekly Profit Analysis & Free Expert Approved Momentum Trade Ideas - Newser
Edwards Lifesciences Stock: Is EW Outperforming The Healthcare Sector? - Barchart.com
Edwards Lifesciences celebrates new ESC guidelines - BioWorld MedTech
Edwards Lifesciences Corporation stock daily chart insightsDip Buying & Safe Entry Zone Tips - Newser
Edwards TAVR Gets Expanded ESC Guidelines for Severe AS Patients - Stock Titan
Edwards praises new aortic valve repair guidelines, reports positive Evoque data - MassDevice
Published on: 2025-08-29 06:42:54 - Newser
DBS Bank Adjusts Price Target on Edwards Lifesciences to $81 From $78, Maintains Hold Rating - MarketScreener
Finanzdaten der Edwards Lifesciences Corp-Aktie (EW)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):